Abstract: OBJECTIVE To establish an accurate, rapid and inexpensive method for the detection of HLA-B*5801 which was a biomarker for allopurinol induced serious cutaneous adverse drug reactions(SCADRs). METHODS Collected 14 Chinese patients with allopurinol-SCADRs and 30 randomly inpatients taking allopurinol more than 14 d with not cutaneous adverse reactions from 2012 January to 2014 December in Fujian Han population. Extracted DNA, then detected HLA-B*5801 by PCR-sequence specific primers (PCR-SSP), PCR-restriction fragment length polymorphism (PCR-RFLP) and polymerase chain reaction-sequence based typing(PCR-SBT). Analyzed the methods of accuracy of results, operation and economy, etc. RESULTS The three methods got the same result. It is found that the allopurinol-SCADRs patients 100%(14/14) had HLA-B*5801, whereas only 23.33% (7/30) in the allopurinol-tolerant patients(OR=90.87, sensitivity=100%, specificity=76.67%). CONCLUSION PCR-SSP and PCR-RFLP were rapid,?inexpensive, high specificity, easy operation and stability assays which would be useful for pre-screening the subjects with HLA-B*5801, very?suitable for?clinical use?in general and have great clinical?value.